Cargando…

Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents

SIMPLE SUMMARY: In recent years, several agents have been tested in randomized clinical trials in addition to anthracycline and taxane-based neoadjuvant chemotherapy (NACT) in early-stage triple-negative breast cancer (TNBC) to improve pathological complete response rate and, ultimately, survival ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garufi, Giovanna, Carbognin, Luisa, Schettini, Francesco, Seguí, Elia, Di Leone, Alba, Franco, Antonio, Paris, Ida, Scambia, Giovanni, Tortora, Giampaolo, Fabi, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454536/ https://www.ncbi.nlm.nih.gov/pubmed/36077601 http://dx.doi.org/10.3390/cancers14174064

Ejemplares similares

Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy
por: Garufi, Giovanna, et al.
Publicado: (2023)

Smoking habit and hospitalization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind the evidence.
por: Garufi, Giovanna, et al.
Publicado: (2020)

BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making
por: Pavese, Francesco, et al.
Publicado: (2022)

The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature
por: Garufi, Giovanna, et al.
Publicado: (2021)

PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives
por: Fuso, Paola, et al.
Publicado: (2022)

Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting
por: Franco, Antonio, et al.
Publicado: (2023)

Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
por: Fabi, Alessandra, et al.
Publicado: (2023)

Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
por: Fabi, Alessandra, et al.
Publicado: (2023)

Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story
por: Piro, Geny, et al.
Publicado: (2019)

The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis
por: Mastrantoni, Luca, et al.
Publicado: (2023)

Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series †
por: Orlandi, Armando, et al.
Publicado: (2020)

Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials
por: Duranti, Simona, et al.
Publicado: (2021)

An Innovative Scoring System to Select the Optimal Surgery in Breast Cancer after Neoadjuvant Chemotherapy
por: Franco, Antonio, et al.
Publicado: (2023)

Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine
por: De Paolis, Elisa, et al.
Publicado: (2023)

Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
por: Dieci, Maria Vittoria, et al.
Publicado: (2022)

Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer
por: Carbognin, Luisa, et al.
Publicado: (2022)

Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
por: Dieci, Maria Vittoria, et al.
Publicado: (2022)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives
por: Carbognin, Luisa, et al.
Publicado: (2019)

Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials
por: Amos, Keith D., et al.
Publicado: (2012)

Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model
por: Carbognin, Luisa, et al.
Publicado: (2020)

Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape
por: Srivastava, Neeharika, et al.
Publicado: (2014)

Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma
por: Kim, Myung-Chul, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy in Breast Cancer: An Advanced Personalized Multidisciplinary Prehabilitation Model (APMP-M) to Optimize Outcomes
por: Di Leone, Alba, et al.
Publicado: (2021)

Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials
por: Mastrantoni, Luca, et al.
Publicado: (2023)

Novel Biomarkers to Guide Immunotherapy De-Escalation in the Neoadjuvant Setting in Triple-Negative Breast Cancer
por: Gandhi, Shipra
Publicado: (2023)

Oligometastatic Breast Cancer: How to Manage It?
por: Barberi, Vittoria, et al.
Publicado: (2021)

Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
por: Ribeiro, Rita, et al.
Publicado: (2022)

Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
por: Marron, Thomas U, et al.
Publicado: (2022)

Immunotherapy in combination with neoadjuvant anthracycline‑free chemotherapy for triple‑negative early breast cancer: A case report
por: Zhao, Xiangwang, et al.
Publicado: (2023)

Level II Oncoplastic Surgery as an Alternative Option to Mastectomy with Immediate Breast Reconstruction in the Neoadjuvant Setting: A Multidisciplinary Single Center Experience
por: Di Leone, Alba, et al.
Publicado: (2022)

Comment on “Abscopal effect in the radio and immunotherapy”
por: Fabi, François
Publicado: (2022)

Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study
por: Trestini, Ilaria, et al.
Publicado: (2021)

Current Landscape of Immunotherapy for Advanced Sarcoma
por: Albarrán, Víctor, et al.
Publicado: (2023)

Development of a Digital Research Assistant for the Management of Patients’ Enrollment in Oncology Clinical Trials within a Research Hospital
por: Cesario, Alfredo, et al.
Publicado: (2021)

Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
por: Garcia, Diogo, et al.
Publicado: (2021)

Immunotherapy for early triple negative breast cancer: research agenda for the next decade
por: Tarantino, Paolo, et al.
Publicado: (2022)

“Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management
por: Sollena, Pietro, et al.
Publicado: (2021)

The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
por: Dibajnia, Pooya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2dsha6pb0a0i9vu2ipeavr4po7